Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1521 to 1530 of 2580 total matches.
Electronic Cigarettes
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013 (Issue 1429)
among
smokers, but also among non-smokers.1,2
THE DEVICES — E-cigarettes are battery-operated
devices ...
Electronic cigarettes, also called e-cigarettes, are advertised
as a safer, more convenient, and socially acceptable
alternative to smoking tobacco cigarettes. Widely
available in retail stores and on the Internet, their use
has been increasing over recent years, primarily among
smokers, but also among non-smokers.
In Brief: Pancreatic Enzyme Replacement Products
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
IN BRIEF
Pancreatic Enzyme Replacement
Products
Table 1. FDA-Approved Pancreatic Enzyme ...
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal FDA approval was required; in 1991, however, the FDA told all manufacturers of pancreatic enzyme replacement products that they would have to submit a new drug application by April 2010 in order to keep their products on the market.EPI is a chronic disorder characterized by a deficiency of exocrine pancreatic enzymes, which results in malabsorption, steatorrhea, and weight loss. Irreversible EPI is...
Firvanq - Vancomycin Oral Solution
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
1. SN Bass et al. Comparison of oral vancomycin capsule and
solution for treatment of initial ...
The FDA has approved vancomycin oral solution
(Firvanq – Cutis Pharma) for treatment of Clostridium
difficile-associated diarrhea and enterocolitis caused
by Staphylococcus aureus, including methicillin-resistant
strains (MRSA).
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
for the same indication in 2020
based on initial overall response rates and duration
of response.1
ADVERSE ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction
New Copper IUD
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988 (Issue 760)
, those 20 to 24 years old had a rate of 3.2, and those 25 years old or
older had a rate of 1.0. The one ...
The copper T 380A (ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which gradually releases progesterone (Medical Letter, 18:65, 1976), is the other.
Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989 (Issue 802)
200 cells/mm
3
or less than 20% of total lymphocytes (H
Masur et al, Ann Intern Med, 111:223, Aug 1 ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
Clozapine for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990 (Issue 809)
blockade,
clozapine has serotonergic, adrenergic, histaminergic (H
1
) and cholinergic blocking activity ...
Clozapine (Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of its toxicity, the labeling for clozapine recommends using the drug only for schizophrenic patients who have not responded adequately to standard antipsychotic drugs or have had intolerable adverse effects.
Prevention And Treatment of Cholera
The Medical Letter on Drugs and Therapeutics • Nov 15, 1991 (Issue 857)
infection is less than 1%. Two types of
V. cholera are pathogenic: the classical biotype, which causes ...
Almost 300,000 cases of epidemic cholera have occurred in the Western Hemisphere in 1991, mostly in South and Central America (Morbid Mortal Weekly Rep, 40:562, Aug 16, 1991). The few US cases caused by the epidemic strain have been in returning travelers or associated with contaminated food they brought back illicitly, with no secondary spread to date.
Topical Drugs for Aging Skin
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997 (Issue 1007)
approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin ...
Topical tretinoin (all-trans-retinoic acid) has been used for years to treat skin damaged by chronic exposure to the sun (Medical Letter, 34:28, 1992). First approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin-A, and others), it has now been approved as an 0.05% formulation in an emollient cream base (Renova) for topical treatment of photodamaged skin. In recent years, alpha-hydroxy acids incorporated in some cosmetics have also been promoted as effective in improving the appearance of aging skin.
Orlistat for Obesity
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999 (Issue 1055)
with placebo. In the second year, patients who stayed on the drug
regained 1.5 to 3 kg, compared to a 4- to 6 ...
Orlistat, a lipase inhibitor that decreases absorption of fat from the gastrointestinal tract, is now available for treatment of obesity.